Format

Send to

Choose Destination
Trends Mol Med. 2011 Feb;17(2):65-77. doi: 10.1016/j.molmed.2010.10.007. Epub 2010 Nov 17.

NKT cell costimulation: experimental progress and therapeutic promise.

Author information

1
Department of Microbiology and Immunology, The University of Western Ontario, London, Ontario, Canada.

Abstract

Invariant natural killer T (iNKT) cells are innate lymphocytes with unique specificity for glycolipid antigens and remarkable immunomodulatory properties. The role of costimulatory interactions in iNKT cell responses has recently come under scrutiny. Although iNKT cells and their prototype glycolipid agonist α-galactosylceramide (α-GalCer) have shown promise in several clinical trials conducted in patients with cancer or viral diseases, current iNKT cell-based therapies are far from effective. The concomitant targeting of T cell receptors (TCRs) and costimulatory molecules on iNKT cells represents an exciting new opportunity to optimize such therapeutic approaches. Here, we review recent advances in our understanding of iNKT cell costimulation and discuss potential treatment modalities based on the responsiveness of iNKT cells to disease-tailored glycolipids and select costimulatory ligands.

PMID:
21087900
PMCID:
PMC3616392
DOI:
10.1016/j.molmed.2010.10.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center